Abstract
Fabry's disease is a recessive X linked genetic disorder in which lysosomal enzyme alpha-galactosidase A activity is affected, with accumulation of different kind of metabolites such as globotriaosylceramide and the deacylated globotriaosylceramide which are responsible for the multi-organ dysfunction that is seen in this disease, and also of the several phenotypic manifestations, mainly in nervous system, skin, gastrointestinal tract, heart and kidney.
Earlier neurological manifestation is neuropathic pain could finding also gastrointestinal tract, skin and eye complaints while Cardiac and renal damage present later like as cerebrovascular disease which presents in adulthood.
Two clinical cases of young patients with cryptogenic stroke with heterozygous mutations for Fabry's disease are presenting below.
References
Alipourfetrati S, Saeed A, Norris JM, Sheckley F, Rastogi A. A Review of Current and Future Treatment Strategies for Fabry Disease: A Model for Treating Lysosomal Storage Disease. J Pharmacol Clin Toxicol. 2015;3(3):1051.
Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249-54.
Germain DP. Fabry disease. Germain Orphanet. Journal of Rare Diseases. 2010;5:30.
Fellgiebel A, Müller MJ, Ginsberg L. CNS manifestations of Fabry's disease. Lancet Neurol. 2006;5(9):791-95.
Kolodny E, Fellgiebel A, Hilz MJ, Sims K, Caruso P, Phan TG, et al. Cerebrovascular Involvement in Fabry Disease Current Status of Knowledge. Stroke. 2015;46(1):302-13.
Tanislav C, Kaps M, Rolfs A, Bottcher T, Lackner K, Paschke E, et al. Frequency of Fabry disease in patients with small-fibre neuropathy of unknown aetiology: a pilot study. Eur J Neurol. 2011;18(4):631-36.
Wu JC, Ho CY, Skali H, Abichandani R, Wilcox WR, Banikazemi M, et al. Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and a-galactosidase A activity. Eur Heart J. 2010;31(9):1088-97.
Sims K, Politei J, Banikazemi M, Lee P. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke. 2009;40(3):788-94. doi: 10.1161/STROKEAHA.108.526293
Rolfs A, Bõttcher T, Zschiesche, M, Morris P, Winchester B, Bauer P, et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet. 2005;366(9499):1794-96.
Politei J, Schenone AB, Burlina A, Blanco M, Lescano S, Szlago M, et al. Vertebrobasilar dolichoectasia in Fabry Disease: the earliest marker of neurovascular involvement?. J Inborn Errors Metab Screening. 2014;2:2326409814541246. doi:10.1177/2326409814541246
Fellgiebel A, Keller I, Martus P, Ropele S, Yakushev I, Bõttcher T , et al. Basilar artery diameter is a potential screening tool for Fabry disease in young stroke patients. Cerebrovasc Dis. 2011;31(3):294-99. doi: 10.1159/000322558
Linthorst GE, Vedder AC, Aerts JM, Hollak CE: Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers. Clin Chim Acta. 2005;353(1-2):201-3.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.